Japan NHI Drug Price Revision 2026: What Changed and Why It Matters
Japan's April 2026 NHI drug price revision cut prices 4.02% on a spending basis. Here's what changed structurally and which drugs were hit hardest.
Japan's April 2026 National Health Insurance (NHI) drug price revision is now in effect. For global market access teams, this is the revision that matters most in the current cycle: it is a full structural revision year, and MHLW used it to push through several rule changes that will shape launch sequencing, lifecycle management, and biosimilar strategy for the next several years.
This article covers the headline numbers, the structural policy changes that distinguish FY2026 from FY2024, and the specific product categories and named drugs that absorbed the largest cuts.
The Headline Numbers and What They Mean
Japan's FY2026 drug price revision produced an average reduction of 4.02% on a drug-expenditure basis, applied across approximately 15,800 listed products. MHLW also reports the cut as 0.86% on a national medical expenditure basis — roughly ¥105.2 billion in central government savings. These two figures describe the same revision; drugs represent roughly one-fifth of total medical spending in Japan, so the math is internally consistent. Reporting that references only the 0.86% figure is using a denominator that includes physician fees, hospital costs, and devices — it understates the actual pressure on pharmaceutical budgets.
For context, the FY2024 full revision came in at 4.67% on a drug-spending basis. FY2026 is somewhat lighter in aggregate, but the composition of cuts shifted in ways that matter more than the headline rate.
The revision generated savings equivalent to 70% of Japan's total FY2026 healthcare reform target of ¥150 billion — a disproportionate load that JPMA flagged in a December 2025 joint statement, noting that pharmaceuticals represent less than 10% of Japan's social security budget but are absorbing the majority of budget reduction targets.
Of the 15,800 products covered:
- 61% received price cuts
- 12% received price increases
- 27% saw no change
How the Revision Cycle Works — and Why 2026 Is Different
Japan historically revised NHI prices every two years in even fiscal years, aligned with the simultaneous revision of medical service fees (診療報酬). That calendar still drives the structural revisions. Since FY2021, however, MHLW has conducted annual interim market surveys and applied repricing in odd years as well, effectively making price adjustment annual. The FY2026 revision is a full revision year, which means structural rule changes to pricing formulas and premium frameworks are on the table in a way they are not in interim years.
This distinction explains why the FY2026 revision contains more policy machinery than most: the G1 expansion to originator biologics, the PMP restructuring, the SPA-SSS framework, and the abolition of the spillover rule all landed simultaneously because this was the window in which they could.
The market-price gap survey — the mechanism that drives annual repricing — also tells a directional story. In the FY2024 survey cycle, the gap between official NHI prices and actual market transaction prices stood at 6.0%, itself a 30-year low at the time. By the FY2026 survey (conducted September 2025), that gap had narrowed further to 4.8%, a new record low. This compression reflects both the increased frequency of revisions pulling official prices toward market reality and persistent cost inflation in the wholesale channel. A narrower gap means less room for future price cuts through the survey mechanism alone — which partly explains why MHLW is tightening structural repricing tools instead.
Key Structural Policy Changes in FY2026
G1 Repricing Extended to Originator Biologics
The most consequential change in FY2026 is the application of the G1 repricing rule to originator biologics. Previously, G1 applied to off-patent small-molecule originators once generics entered the market. Under the FY2026 framework, a biologic originator is now subject to G1 repricing if its biosimilar is listed on the NHI formulary — regardless of the biosimilar's market penetration rate.
The impact is immediate and measurable. Among off-patent biologics, 95% recorded price reductions in the April 2026 revision. Among off-patent small-molecule originators, 69% recorded decreases, up from 57% in FY2024. Companies running originator biologic maintenance strategies in Japan must now assume G1-level price exposure at biosimilar listing, not at some substitution rate threshold.
Patent-Period Price Maintenance Program: Renamed, Restructured, and Now Carrying a Repayment Liability
The Price Maintenance Premium (PMP) — the mechanism that allowed innovative branded drugs to maintain NHI prices during their patent-protected period by exempting them from standard market survey-based cuts — has been renamed the Patent-Period Price Maintenance Program for Innovative Drugs. The name change is not merely cosmetic.
The FY2026 revision formalizes what had been signaled in FY2025: accumulated PMP benefits must be repaid as a lump-sum price reduction at the moment generics or biosimilars enter the market. The brand product loses its survey-cut exemption and simultaneously absorbs a catch-up repricing to account for the price gap that had been protected. In prior cycles, this repayment was smoother and spread across revision rounds; FY2026 makes the cliff steeper.
Forxiga (dapagliflozin, AstraZeneca) illustrates the dynamic. Generics entered the Japanese market in December 2025 at approximately 34% of the brand price. In April 2026, Forxiga absorbed a reported 36% price cut driven by PMP return across its diabetes, heart failure, and chronic kidney disease indications combined — a simultaneous multi-indication reset.
On the positive side, FY2026 expands the set of drugs eligible for PMP in the first place, and allows products to receive both the marketability premium and the pediatric development premium simultaneously, which had not previously been permitted.
SPA-SSS: The Blockbuster Repricing Ceiling Rises
The longstanding "huge seller repricing" rule — which applied additional price cuts to drugs with sales dramatically exceeding original forecasts — has been rebranded as the Special Price Adjustment for Sustainable Health System and Sales Scale (SPA-SSS). The substantive change is significant: the maximum price reduction ceiling under this mechanism rises from 50% to 66.7%, applicable when annual sales exceed ¥300 billion and reach at least 10 times the original sales forecast. No product currently hits this threshold, but the rule signals MHLW's posture toward future blockbusters.
Spillover Rule Abolished
The FY2026 revision abolishes the spillover rule, which had automatically extended Market Expansion Repricing (MER) price cuts to therapeutically similar drugs when a product in the class triggered MER. JPMA and industry groups had long argued this rule penalized drugs for commercial success in related indications and created perverse incentives around indication filing. MHLW retains class-level monitoring authority but removed the automatic propagation mechanism.
International Reference Pricing Basket Updated
Japan's foreign reference pricing mechanism now incorporates post-AMNOG negotiated prices from Germany rather than free-market launch prices. Since Germany's AMNOG process typically produces net prices significantly below list, this change narrows the reference basket upward boundary and compresses the adjustment corridor for drugs with high German launch prices.
Product-Level Impact: What Got Cut and By How Much
The following table summarizes reported price changes for selected branded products in the April 2026 revision.
| Product | INN | Company | Reported Cut | Driver |
|---|---|---|---|---|
| Avastin | bevacizumab | Roche | ~45% | G1 (biosimilar competition) |
| Forxiga | dapagliflozin | AstraZeneca | ~36% | PMP return at generic entry |
| Eylea | aflibercept | Bayer/Regeneron | Significant | PMP return (biosimilar listed) |
| Actemra | tocilizumab | Roche | Significant | G1 (biosimilar competition) |
| Zytiga | abiraterone | J&J | Reported ~40% | PMP-driven repricing |
| Abraxane | paclitaxel albumin-bound | Taiho | >30% | Post-patent repricing |
Note: Figures for Eylea, Actemra, and Zytiga are reported from industry analysis rather than MHLW official disclosures; treat as directional.
Avastin's ~45% cut reflects the full impact of G1 applied to an originator biologic with established biosimilar competition. It is among the largest single-product cuts in the April revision and signals what the expanded G1 rule means in practice for other high-value biologics with biosimilars in the queue.
What This Means for Market Access Strategy
The FY2026 revision does not represent a fundamental break from Japan's cost-containment trajectory, but it accelerates several dynamics that were already in motion.
At launch: The PMP program is still worth pursuing for eligible innovative drugs. The FY2026 expansion of simultaneous marketability and pediatric premiums improves the economics for sponsors with paediatric programs. However, teams should model the PMP repayment liability at generic/biosimilar entry explicitly — it is now a lump-sum cliff, not a gradual slope.
For branded biologics: The extension of G1 to originator biologics is the single most impactful structural change of this revision. Any originator biologic strategy in Japan must now assume a hard price reset at biosimilar NHI listing. Companies relying on market share maintenance post-biosimilar entry to sustain revenue will find the pricing floor drops faster than it did under previous rules.
On the access paradox: Industry data cited in the JPMA December 2025 statement notes that approximately 44% of medicines approved in the United States between 2005 and 2022 never reached Japanese patients. The annualized revision schedule and increasingly aggressive repricing mechanisms have sharpened launch sequencing risk. Some sponsors are explicitly deprioritizing Japan launch timing, which MHLW has acknowledged as an unintended consequence — the FY2027 revision cycle will almost certainly revisit the innovation incentive framework again.
The structural signals from FY2026 are clear: innovators are protected during patent life if they qualify for PMP, but the rules at patent expiry are now steeper and faster than any prior cycle. For market access teams planning Japan submissions over the next three to five years, the lifecycle management model needs to be redrawn accordingly.
Track Japan NHI prices in English
NHI Price Wire gives pharma market access teams a searchable English dashboard of all 17,000+ NHI drug prices, updated automatically with every MHLW revision.
Start 14-day free trial →